Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - Cancer discovery, 2014 - AACR
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAFV600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …
被引用次数：86 相关文章
[PDF] academia.edu

[PDF][PDF] Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF-and NRAS-Mutant Malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - 2014 - academia.edu
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF V600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF-and NRAS-Mutant Malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - 2014 - scholarworks.unist.ac.kr
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF (V600)-mutant
melanoma but activates extracellular signal-regulated kinase (ERK) signaling in RAS …
[PDF] researchgate.net

[PDF][PDF] Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF-and NRAS-Mutant Malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - 2014 - researchgate.net
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF V600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell… - Cancer …, 2014 - pubmed.ncbi.nlm.nih.gov
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF (V600)-mutant
melanoma but activates extracellular signal-regulated kinase (ERK) signaling in RAS …

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies.

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - Cancer …, 2014 - europepmc.org
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF V600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …
[HTML] nih.gov

[HTML][HTML] Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF-and NRAS-Mutant Malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - Cancer …, 2014 - ncbi.nlm.nih.gov
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF V600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …
[PDF] psu.edu

[PDF][PDF] Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF-and NRAS-Mutant Malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - 2014 - Citeseer
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF V600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies.

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - Cancer …, 2014 - europepmc.org
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF V600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …
[PDF] researchgate.net

[PDF][PDF] Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF-and NRAS-Mutant Malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - 2014 - researchgate.net
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF V600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS …